(Tell me in the comments #ObesityMedicine #GLP1 #WeightManagement #FDAApproval #ClinicalPharmacy #MedicationAccess #PublicHealth #HealthEquity #ThePublicHealthPharmacist To view or add a comment, sign in The FDA has granted expedited approval to Eli Lilly's new weight-loss pill, orforglipron (Foundayo), marking it as the second daily oral GLP-1 medication for obesity
264 LiuCGuoXBaiSZengGWangH
Skip MEDVi oral tirzepatide until absorption data exists
Roughly half (54%) of people who have used GLP-1 medications say it was somewhat or very difficult to afford them, including 53% of those with health insurance
Downstream Hepatic IGF-1 Modulation: Tracking longitudinal transcriptomic shifts in hepatic tissue models following extended dual-agonist exposure, specifically mapping the conversion of pulsatile growth hormone surges into steady-state Insulin-like Growth Factor-1 (IGF-1) transcription loops
These results were attributed not just to improved glycemic control, but to anti-inflammatory effects on arterial walls, reduced plaque formation, and enhanced endothelial function